|
Persistent Identifier
|
perma:LIST.AMWNSU |
|
Publication Date
|
2026-07-06 |
|
Title
| The multilayered transcriptional architecture of glioblastoma ecosystems [* Cross-Reference *] |
|
Other Identifier
| https://doi.org/10.1038/s41588-025-02167-5
OpenAlex ID: https://openalex.org/W4410242531 |
|
Author
| Masashi Nomura (Broad Institute, Harvard University, Massachusetts General Hospital, Center for Cancer Research, The University of Tokyo) - ORCID: https://orcid.org/0000-0001-6095-7849
Avishay Spitzer (Tel Aviv University, Tel Aviv Sourasky Medical Center, Weizmann Institute of Science) - ORCID: https://orcid.org/0000-0001-6551-9338
Kevin C. Johnson (Yale University) - ORCID: https://orcid.org/0000-0003-0016-5158
Luciano Garofano (University of Miami, Sylvester Comprehensive Cancer Center) - ORCID: https://orcid.org/0000-0001-8582-0865
Djamel Nehar-Belaid (Jackson Laboratory) - ORCID: https://orcid.org/0000-0001-6002-5021
Noam Galili Darnell (Weizmann Institute of Science)
Alissa Greenwald (Weizmann Institute of Science) - ORCID: https://orcid.org/0000-0001-5428-9645
Lillian Bussema (Broad Institute, Harvard University, Massachusetts General Hospital, Center for Cancer Research) - ORCID: https://orcid.org/0000-0001-5469-3816
Young Taek Oh (University of Miami, Sylvester Comprehensive Cancer Center) - ORCID: https://orcid.org/0000-0001-8356-2428
Frederick S. Varn (University of Connecticut, Jackson Laboratory, UConn Health) - ORCID: https://orcid.org/0000-0001-6307-016X
Fulvio D’Angelo (University of Miami, Sylvester Comprehensive Cancer Center, Neurological Surgery) - ORCID: https://orcid.org/0000-0002-4940-4693
Simon Gritsch (Broad Institute, Harvard University, Massachusetts General Hospital, Center for Cancer Research) - ORCID: https://orcid.org/0000-0001-5682-5712
Kevin Anderson (Jackson Laboratory) - ORCID: https://orcid.org/0000-0002-2362-273X
Simona Migliozzi (University of Miami, Sylvester Comprehensive Cancer Center)
L. Nicolas Gonzalez Castro (Broad Institute, Brigham and Women's Hospital, Harvard University, Massachusetts General Hospital, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Center for Cancer Research) - ORCID: https://orcid.org/0000-0001-7699-5188
Tamrin ChowdhFury (Yale University)
Nicolas Robine (New York Genome Center) - ORCID: https://orcid.org/0000-0001-5698-8183
Catherine Reeves (New York Genome Center) - ORCID: https://orcid.org/0000-0002-9942-8909
Jong Bae Park (National Cancer Center) - ORCID: https://orcid.org/0000-0003-0207-0697
Anuja Lipsa (Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0002-9668-6048
Frank Hertel (Luxembourg Institute of Health)
Anna Golebiewska (Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0002-4160-2521
Simone P. Niclou (University of Luxembourg, Luxembourg Institute of Health, Luxembourg Institute of Science and Technology) - ORCID: https://orcid.org/0000-0002-3417-9534
Labeeba Nusrat (St. Michael's Hospital, University of Toronto)
Sorcha Kellet (St. Michael's Hospital, University of Toronto)
Sunit Das (St. Michael's Hospital, University of Toronto) - ORCID: https://orcid.org/0000-0002-2146-4168
Hyo Eun Moon (Cancer Research Institute)
Sun Ha Paek (Seoul National University, Cancer Research Institute, Advanced Institute of Convergence Technology) - ORCID: https://orcid.org/0000-0003-3007-8653
Franck Bielle (Centre National de la Recherche Scientifique, Inserm, Sorbonne Université, Sorbonne Paris Cité, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital) - ORCID: https://orcid.org/0000-0001-6564-6388
Alice Laurenge (Centre National de la Recherche Scientifique, Inserm, Sorbonne Université, Sorbonne Paris Cité, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital) - ORCID: https://orcid.org/0000-0002-0058-3176
Anna Luisa Di Stefano (Ospedale di Livorno, Hôpital Foch) - ORCID: https://orcid.org/0000-0003-1746-0647
Bertrand Mathon (Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital) - ORCID: https://orcid.org/0000-0002-9182-5846
Alberto Pïcca (Centre National de la Recherche Scientifique, Inserm, Sorbonne Université, Sorbonne Paris Cité, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital) - ORCID: https://orcid.org/0000-0001-7807-5393
Marc Sanson (Centre National de la Recherche Scientifique, Inserm, Brain Tumour Charity, Sorbonne Université, Sorbonne Paris Cité, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital) - ORCID: https://orcid.org/0000-0002-1813-8476
Shota Tanaka (The University of Tokyo)
Nobuhito Saito (The University of Tokyo) - ORCID: https://orcid.org/0000-0001-9756-781X
David M. Ashley (Pediatric Brain Tumor Foundation) - ORCID: https://orcid.org/0000-0002-4754-5900
Stephen T. Keir (Pediatric Brain Tumor Foundation) - ORCID: https://orcid.org/0000-0001-8630-3587
Keith L. Ligon (Brigham and Women's Hospital, Dana-Farber Cancer Institute) - ORCID: https://orcid.org/0000-0002-7733-600X
Jason T. Huse (The University of Texas MD Anderson Cancer Center) - ORCID: https://orcid.org/0000-0003-4514-0640
W.K. Alfred Yung (The University of Texas MD Anderson Cancer Center) - ORCID: https://orcid.org/0000-0002-1669-0793
Anna Lasorella (University of Miami, Sylvester Comprehensive Cancer Center) - ORCID: https://orcid.org/0000-0002-1839-5421
Roel G.W. Verhaak (Yale University, Amsterdam University Medical Centers, University of Amsterdam) - ORCID: https://orcid.org/0000-0003-2773-0436
Antonio Iavarone (University of Miami, Sylvester Comprehensive Cancer Center) - ORCID: https://orcid.org/0000-0002-0683-4634
Mario L. Suvà (Broad Institute, Massachusetts General Hospital, Center for Cancer Research) - ORCID: https://orcid.org/0000-0001-9898-5351
Itay Tirosh (Weizmann Institute of Science) - ORCID: https://orcid.org/0000-0001-5477-2987 |
|
Point of Contact
|
Use email button above to contact.
LIST QDKM (LIST) |
|
Description
| In isocitrate dehydrogenase wildtype glioblastoma (GBM), cellular heterogeneity across and within tumors may drive therapeutic resistance. Here we analyzed 121 primary and recurrent GBM samples from 59 patients using single-nucleus RNA sequencing and bulk tumor DNA sequencing to characterize GBM transcriptional heterogeneity. First, GBMs can be classified by their broad cellular composition, encompassing malignant and nonmalignant cell types. Second, in each cell type we describe the diversity of cellular states and their pathway activation, particularly an expanded set of malignant cell states, including glial progenitor cell-like, neuronal-like and cilia-like. Third, the remaining variation between GBMs highlights three baseline gene expression programs. These three layers of heterogeneity are interrelated and partially associated with specific genetic aberrations, thereby defining three stereotypic GBM ecosystems. This work provides an unparalleled view of the multilayered transcriptional architecture of GBM. How this architecture evolves during disease progression is addressed in the companion manuscript by Spitzer et al. (2025-05-01)
***This entry has been automatically imported via OpenAlex by LIST harvest scripts. Please refer to https://doi.org/10.1038/s41588-025-02167-5 for the original and latest version of the publication*** (2026-07-01) |
|
Subject
| Chemistry; Medicine, Health and Life Sciences |
|
Keyword
| Biology
Glioblastoma
Ecosystem
Architecture
Computational biology
Evolutionary biology
Ecology
Genetics
Cancer research
Archaeology |
|
Topic Classification
| Single-cell and spatial transcriptomics
Genomics and Chromatin Dynamics
Glioma Diagnosis and Treatment |
|
Deposit Date
| 2025-05-01 |
|
Data Type
| Article |
|
Data Source
| Nature Genetics |